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Aim: To investigate changes in tumor sizes and pathological tumor stages in patients undergoing surgery for renal mass between 2000
and 2011.
Materials and methods: The data of 157 patients who underwent surgery for renal mass, including TNM stage, size, and Fuhrman grade
at final pathology, were evaluated retrospectively.
Results: The mean pathological size of the tumor in the whole population of the study was 6.97 cm. The mean size of the renal mass was
7.22 cm, 7.05 cm, and 6.91 cm in group 1, group 2, and group 3, respectively, and the difference was not statistically significant. Of the
renal cell carcinomas, 57.2% were stage I, 22.7% were stage II, 10.3% were stage III, and 9.6% were stage IV. Differences between groups
in terms of changes in tumor stage were not statistically significant.
Conclusion: We observed that there was no downward stage migration in renal cell carcinoma during the 12-year study period.
Key words: Renal cell carcinoma, stage migration, histology, grade

1. Introduction
The incidence of renal cell carcinoma (RCC) is globally
more than 200,000 cases every year (1). RCC is the
most common malignant tumor of the kidney (2). RCC
is more prevalent in men than in women, and it occurs
most frequently at 50–70 years of age (3). The incidence
of RCC has increased by 3%–4% on average per year since
the 1970s. The changes in prevalence are associated with
potential risk factors such as hypertension, smoking,
and obesity, as well as being largely related to the more
widespread use of abdominal imaging modalities for the
diagnosis of a variety of abdominal and pelvic problems
(4).
Depending on the prevalence of the use of
ultrasonography and computerized tomography (CT),
there are different results for downward stage migration
over time (5). The detection rate of tumors at lower stages
and smaller sizes has been reported to have increased in
US and European publications (6–8).
On the other hand, a retrospective study from Australia
showed a different and striking result, which was that there
was no significant stage and size alteration between 1993
and 2007 (9).
* Correspondence: estkorgali@hotmail.com

Since our clinical observations are not different from the
results of the Australian study, we intended to investigate
the changes in renal tumor size and pathological tumor
stage in patients undergoing surgery at our center between
2000 and 2011.
2. Materials and methods
All patients undergoing partial or radical nephrectomy
with a renal mass diagnosis performed by 4 surgeons at
Cumhuriyet University Medical Faculty, Department of
Urology, between January 2000 and December 2011 were
included in the study. The recorded data of 174 consecutive
patients were examined, including patient demographics,
TNM stage, size, and Fuhrman grade at final pathology,
and the data of 157 patients with accessible complete
information were evaluated retrospectively.
Tumors were staged according to the 2004 edition TNM
classification system, and cases diagnosed before 2004
were restaged using 4th edition criteria (10). T stage, or
tumor size, was recorded the largest tumor diameter (cm)
reported in the final pathology report. Table 1 illustrates
the clinicopathological parameters of 157 patients.
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Table 1. Clinicopathological parameters of the entire study cohort (n = 157).

Sex

Male
Female

Number

%

89

56.7

68

43.3

Age (years)
61.46 ± 12.09
Tumor size (cm)
6.97 ± 3.718
Median (interquartile range): 6
(1–20)
Pathologic stage
pT1
pT2
pT3
pT4

83
33
15
14

57.2
22.7
10.3
9.6

121
15
8
1

83.4
10.3
5.5
0.6

8
4

66.6
33.3

1
67
46
31

0.6
46.2
31.7
21.3

Histology
Clear cell RCC
Papillary RCC
Chromophobe RCC
Mucinous tubular and spindle cell
Benign tumors
Oncocytoma
Angiomyolipoma
Nuclear grade (Fuhrman)
G1
G2
G3
G4

The data were divided into 3 equal time periods: group
1, from 1 January 2000 to 31 December 2003; group 2, from
1 January 2004 to 31 December 2007; and group 3, from
1 January 2008 to 31 December 2011. The significance of
trends in histological subtype, Fuhrman nuclear grade,
tumor size, sex distribution, and benign lesions were also
assessed.
The results were analyzed using SPSS 14. The chi-square
test and analysis of variance were used, and a P-value of
less than 0.05 was considered significant. All procedures
were performed in accordance with the ethical guidelines
of the Cumhuriyet University Medical Faculty.
3. Results
No reliable staging record was available in the data of 18
patients. We were able to fully evaluate the data of the
remaining 157 patients.
The average age of the patients was 61.6 years (ranging
between 10 and 86 years). Overall, there were 23 cases in
group 1 (2000–2003), 40 cases in group 2 (2004–2007), and
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94 cases in group 3 (2008–2011). With respect to age, there
was not a significant difference at the diagnosis during the
study period; the average ages of the patients at operation
time were 63.30 years for group 1, 60.31 years for group 2,
and 62.50 years for group 3 (P = 0.484).
The male-to-female ratio in the study population was
1.32 (89 men and 68 women). The between-group sex ratio
was similar, and changes over time were not statistically
significant (P = 0.319).
The mean pathological size of the tumor in the whole
study population was 6.97 cm (1–20 cm). The mean size of
the renal mass was 7.22 cm, 7.05 cm, and 6.91 cm in group
1, group 2, and group 3, respectively, and the difference
was not statistically significant
(P = 0.45).
During the 12-year period, 57.2% of RCCs were stage
I, 22.7% were stage II, 10.3% were stage III, and 9.6%
were stage IV. The difference between groups in terms of
changes in tumor stage was not statistically significant (P
= 0.424) (Table 2; Figure 1).
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Table 2. RCC stage percentage distribution by time period: n (%).
Groups

pT1

pT2

pT3

pT4

2000–2003
2004–2007
2008–2011

13 (56.5)
20 (60.60)
50 (56.17)

5 ( 21.7)
8 (24.24)
20 (22.47)

2 (8.7)
3 (9.09)
10 (11.23)

3 (13.0)
2 (6.06)
9 (10.11)

21.3% were Fuhrman grade IV. When changes between the
groups were evaluated, a statistically significant increase
was observed in the rate of Fuhrman III and Fuhrman IV
(P = 0.03) (Table 4; Figure 3).

70.00%
60.00%
pT1
pT2
pT3
pT4

50.00%
40.00%
30.00%

120.00%
100.00%
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2000–2003
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Figure 1. RCC pathological stage distribution by diagnosis year
groups.

The most frequent histologic subtype of kidney cancers
was clear cell renal carcinoma, in 119 out of 157 patients,
followed by 14 papillary, 10 chromophobe, and 1 mucinous
tubular and 1 spindle cell. Tumors were reported to be
benign in 12 cases; 8 of these were oncocytomas and 4
were angiomyolipomas. Table 1 illustrates the distribution
of the histology types of all cases, and Table 3 illustrates the
distribution of the histology types for groups. Although
the difference was not statistically significant, a decreasing
trend was observed in the number of clear cell conventional
carcinomas (P = 0.207) (Figure 2). It was observed that
there was an increase in the papillary renal cell cancer rate
from 4.3% in group 1 to 7.5% in group 2 and 11.7% group
3; however, the difference was not statistically significant
(P = 0.207).
Fuhrman nuclear grade, which is considered to be
another prognostic factor for RCC, was assessed in 145 out
of 157 cases, and 0.6% were Fuhrman grade I, 46.2% were
Fuhrman grade II, 31.7% were Fuhrman grade III, and
Table 3. RCC histological subtype* percentage distribution by
time period: n (%).
Groups

Clear cell RCC

Papillary RCC

Chromophobe RCC

2000–2003

22 (95.65)

1 (4.37)

0 (0)

2004–2007

27 (81.81)

3 (9.09)

2 (6.06)

2008–2011

72 (80.89)

11 (12.35)

6 (6.74)

*Mucinous tubular and spindle cell carcinoma not included.
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Figure 2. RCC histological distribution by diagnosis year groups.
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Figure 3. RCC Fuhrman grade distribution by diagnosis year
groups.

4. Discussion
RCC constitutes 3% of all adult solid tumors (11). The
incidence of RCC increases by about 3% per year (4).
The results of this study revealed an upward migration in
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Table 4. RCC Fuhrman grade percentage distribution by time period: n (%).
Groups

Fuhrman 1

Fuhrman 2

Fuhrman 3

Fuhrman 4

2000–2003
2004–2007
2008–2011

1 (4.34)
0 (0)
0 (0)

16 (69.56)
16 (48.48)
35 (39.32)

5 (21.73)
10 (30.30)
31 (34.83)

1 (4.34)
7 (21.21)
23 (25.84)

Fuhrman grade from I–II to III–IV, whereas no migration
in stage existed in patients with RCC who underwent
surgery in our institution during the last 12 years.
Luciani et al. reported that the proportion of clinical
stage T1–T2 tumors increased from 49% to 74%, while
the percentage of patients with M1 disease decreased
from 20% to 10%. Similar patterns have been noted for
pathologic stage (6). In a retrospective study conducted
on a great number of patients undergoing surgery
between 1993 and 2004, researchers found an increasing
representation of stage I tumors, from 51 to 60%, and
decreasing proportions of stage II and III disease (7). The
results of another study from Europe, in which 2333 RCC
cases were evaluated retrospectively within a period of 25
years, showed a downward stage migration towards organconfined tumors, with an increasing representation of
pT1–pT2 tumors and decreasing proportions of pT3–pT4
tumors (8). In this study, there was no stage migration, in
contrast to Europe- and US-based studies. In another study
from Australia, Doeuk et al. evaluated the pathological
results of 547 patients undergoing radical or partial
nephrectomy between January 1993 and December 2007,
and they reported that they did not observe any migration
towards earlier-stage and smaller RCCs, in line with this
study (9). However, in both studies, the assessment of
downward stage migration at presentation cannot be
fully achieved in terms of study design. Although cases
were appropriately stratified by stage according to year
at diagnosis, a significant limitation in interpreting the
results of both studies is the inclusion of only surgically
treated cases, with no mention of the incidence of renal
mass lesions on imaging criteria alone or the numbers
of patients included in active surveillance programs. It is
obvious that all informative data regarding the change in
the proportions of stages, grades, mass sizes, and histologic
subtypes should have included not only operated cases
but also the proportion of biopsy-confirmed cases of
RCC managed by active surveillance or by probe-ablative
therapies. In addition to these tangible limitations, we
think that general belief about the widespread use of
abdominal imaging techniques is not applicable in the
world as a whole, and the failure of providing health care
may be responsible for this contradiction.
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Pichler et al. reported that the clear cell RCC rate
was 82%, the papillary RCC rate was 10.9%, and the
chromophobe RCC rate was 3% (8). The rates determined
in this study were 77.6% for clear cell RCC, 9% for papillary
RCC, and 5.1% for chromophobe RCC. The histology
types in this study showed patterns of frequency similar to
those in other studies (7,9).
Another finding in this study was that an upward
migration of Fuhrman grade towards III–IV tumors was
determined in course of the time. The rates of Fuhrman III
and IV increased from 21.7% and 4.3% to 33% and 24.5%,
comparable to the findings of Doeuk et al., who reported
that the rates of Fuhrman III and IV increased from
17.6% and 6.8% to 30.8% and 8.3% (9). However, Pichler
et al. reported no change in Fuhrman grade in a 25-year
period at a European center (8). The reason for this is not
so obvious; however, the Fuhrman nuclear grade is not
objective, and the prognostic role of the Fuhrman grading
system is restricted by its subjective nature and observer
instability because of the poor characterization of nuclear
and nucleolar characteristics. We think that it could
represent changing patterns of scoring by pathologists.
The greatest frequency of benign lesions in renal
tumors is smaller than 3 cm, as previously published
(12–14). This study concludes that benign lesion sizes
are much larger than those reported in other studies.
According to our findings, the mean sizes of oncocytoma
and angiomyolipoma were 5.25 cm and 6.50 cm,
respectively. This difference may be associated with the
assessment of only masses that were removed by radical
or partial nephrectomies. Cases diagnosed by biopsy and
monitoring of small sizes were not included in this study.
In conclusion, we observed that there was no downward
stage migration in RCC during the 12-year study period at
our institution. Although it remains valid only for operated
cases, which themselves are subject to surgeon selection
bias, we think that shifts in stages and other parameters
of diseases may show regional differences throughout the
world.
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